Advertisement

American Journal of Cardiovascular Drugs

, Volume 19, Issue 6, pp 569–577 | Cite as

A Long-Term Cost-Effectiveness Analysis Comparing Radiofrequency Catheter Ablation with Antiarrhythmic Drugs in Treatment of Chinese Patients with Atrial Fibrillation

  • Xin Du
  • Xiaonan He
  • Yu Jia
  • Jiahui Wu
  • Deyong Long
  • Ronghui Yu
  • Caihua Sang
  • Hongjun Yin
  • Jianwei Xuan
  • Jianzeng Dong
  • Changsheng MaEmail author
Original Research Article

Abstract

Introduction

Radiofrequency catheter ablation (RFCA) is widely used to treat atrial fibrillation (AF) in China.

Objective

We aimed to determine the long-term cost effectiveness of RFCA versus antiarrhythmic drugs (AADs) in treating AF from the perspective of third-party payers.

Methods

The model was structured as a 12-month decision tree leading to a Markov model that simulated the follow-up treatment outcomes and costs with time horizons of 8, 15, and 20 years. Comparators were standard-of-care AADs. Clinical parameters captured normal sinus rhythm, AF, stroke, post-stroke, intracranial hemorrhage (ICH), gastrointestinal bleeding, post-ICH, and death. The risk of operative death, procedural complications, and adverse drug toxicity were also considered. The model output was quality-adjusted life-years (QALYs) and incremental cost per QALY gained.

Results

RFCA incurred more costs than the AADs but resulted in more QALYs gained than did AADs. The incremental cost per QALY gained with RFCA versus AADs was ¥66,764, ¥36,280, and ¥29,359 at 8, 15, and 20 years, respectively. The sensitivity analyses showed that the results were most sensitive to the changes in RFCA cost and CHADS2 score (clinical prediction rule for assessing the risk of stroke in patients with non-rheumatic AF).

Conclusion

Compared with AADs, RFCA significantly improves clinical outcomes and QALYs among patients with paroxysmal or persistent AF. From the Chinese payer’s perspective, RFCA is a cost-effective therapy over long-term horizons.

Notes

Acknowledgements

This study was supported by an unrestricted grant from Johnson & Johnson Medical (China) Ltd.

Author Contributions

XD, XH, YJ, JX, and CM designed and led the study. XD, XH, JW, DL, RY, CS, JD, and CM contributed to the clinical investigation and data collection. XD, YJ, JH, HY, JX, and CM participated in the model development, data analysis, and interpretation of results. XD, XH, YJ, JW, DL, RY, CS, HY, JX, JD, and CM contributed to the study management, discussions, and study report and manuscript preparation. All authors read and approved the final manuscript.

Compliance with Ethical Standards

Ethics approval

This article does not contain any studies performed with human or animal participants.

Informed consent

Not applicable.

Availability of data and materials

The datasets used for the cost-effectiveness analysis are not publicly available but may be available from the corresponding author on reasonable request.

Conflict of interest

XD, HY, JX, and CM received research funding from Johnson & Johnson Medical (China) Ltd. YJ is an employee at Johnson & Johnson Medical (China) Ltd. XH, JW, DL, RY, CS, and JD have no conflicts of interest that are directly relevant to the content of this article.

References

  1. 1.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–8.CrossRefGoogle Scholar
  2. 2.
    Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of Mainland China. J Epidemiol. 2008;18(5):209–16.CrossRefGoogle Scholar
  3. 3.
    Boriani G, Diemberger I, Biffi M, Martignani C, Branzi A. Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs. 2004;64:2741–62.CrossRefGoogle Scholar
  4. 4.
    Hamer ME, Blumenthal JA, McCarthy EA, et al. Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal superventricular tachycardia. Am J Cardiol. 1994;74(8):826–9.CrossRefGoogle Scholar
  5. 5.
    Singh SN, Tang XC, Singh BN, et al. Quality of life and exercise performance in patients in sinus rhythm versus persistent atrial fibrillation. J Am Coll Cardiol. 2006;48(4):721–30.CrossRefGoogle Scholar
  6. 6.
    Mont L, Bisbal F, Hernández-Madrid A, SARA Investigators, et al. Catheter ablation vs. antiarrhythmic drug treatment of persistent atrial fibrillation: a multicentre, randomized, controlled trial (SARA study). Eur Heart J. 2014;35(8):501–7.CrossRefGoogle Scholar
  7. 7.
    Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective, multi-centre, randomized, controlled study (Catheter Ablation for the Cure of Atrial Fibrillation Study). Eur Heart J. 2006;27(2):216–21.CrossRefGoogle Scholar
  8. 8.
    Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation. JAMA. 2005;293:2634–40.CrossRefGoogle Scholar
  9. 9.
    Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation the A4 study. Circulation. 2008;118:2498–505.CrossRefGoogle Scholar
  10. 10.
    Weerasooriya R, Jaïs P, Le Heuzey JY, et al. Cost analysis of catheter ablation for paroxysmal atrial fibrillation. Pacing Clin Electrophysiol. 2003;26:292–4.CrossRefGoogle Scholar
  11. 11.
    Khaykin Y, Wang X, Natale A, et al. Cost comparison of ablation versus antiarrhythmic drugs as first-line therapy for atrial fibrillation: an economic evaluation of the RAAFT pilot study. J Cardiovasc Electrophysiol. 2009;20:7–12.CrossRefGoogle Scholar
  12. 12.
    Khaykin Y, Morillo CA, Skanes AC, McCracken A, Humphries K, Kerr CR. Cost comparison of catheter ablation and medical therapy in atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18:907–13.CrossRefGoogle Scholar
  13. 13.
    Rodgers M, McKenna C, Palmer S, et al. Curative catheter ablation in atrial fibrillation and typical atrial flutter: systematic review and economic evaluation. Health Technol Assess. 2008;12:1–198.CrossRefGoogle Scholar
  14. 14.
    Aronsson M, Walfridsson H, Janzon M, et al. The cost effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy. Europace. 2015;17(1):48–55.CrossRefGoogle Scholar
  15. 15.
    Chan PS, Vijan S, Morady F, Oral H. Cost-effectiveness of radiofrequency catheter ablation for atrial fibrillation. J Am Coll Cardiol. 2006;47:2513–20.CrossRefGoogle Scholar
  16. 16.
    Hu S, Zhan L, Liu B, et al. Economic burden of individual suffering from atrial fibrillation-related stroke in China. Value Health Reg Issues. 2013;2(1):135–40.CrossRefGoogle Scholar
  17. 17.
    Neyt M, Van Brabandt H, Devos C. The cost–utility of catheter ablation of atrial fibrillation: a systematic review and critical appraisal of economic evaluations. BMC Cardiovasc Disord. 2013;26(13):78.  https://doi.org/10.1186/1471-2261-13-78.CrossRefGoogle Scholar
  18. 18.
    Guo Y, Tian Y, Wang H, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147(1):109–19.CrossRefGoogle Scholar
  19. 19.
    Xin D, Wu J, Guo X, et al. Clinical outcomes and health-related quality of life of catheter ablation vs. anti-arrhythmia drug therapy among atrial fibrillation patients in China. Circulation. 2015;132:A14799. http://circ.ahajournals.org/content/132/Suppl_3/A14799.short. Accessed 8 Sept 2016.
  20. 20.
    McKenna C, Palmer S, Rodgers M, et al. Cost-effectiveness of radiofrequency catheter ablation for the treatment of atrial fibrillation in the United Kingdom. Heart. 2009;95(7):542–9.CrossRefGoogle Scholar
  21. 21.
    Assasi N, Blackhouse G, Xie F, et al. Ablation procedures for rhythm control in patients with atrial fibrillation: clinical and cost-effectiveness analyses [Technology Report, No. 128]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2010.Google Scholar
  22. 22.
    Siu CW, Lip GY, Lam KF, Tse HF. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. Heart Rhythm. 2014;11(8):1401–8.CrossRefGoogle Scholar
  23. 23.
    GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRefGoogle Scholar
  24. 24.
    Sun S, Chen J, Johannesson M, et al. Population health status in China: EQ-5D results, by age, sex and socio-economic status, from the National Health Services Survey 2008. Qual Life Res. 2011;20(3):309–20.CrossRefGoogle Scholar
  25. 25.
    Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93:118–24.CrossRefGoogle Scholar
  26. 26.
    Statistical Communiqué of the PR CHINA on the 2014 National Economic and Social Development. http://www.stats.gov.cn/english/PressRelease/201502/t20150228_687439.html. Accessed 6 Sept 2016.

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Xin Du
    • 1
  • Xiaonan He
    • 1
  • Yu Jia
    • 2
  • Jiahui Wu
    • 1
  • Deyong Long
    • 1
  • Ronghui Yu
    • 1
  • Caihua Sang
    • 1
  • Hongjun Yin
    • 3
  • Jianwei Xuan
    • 3
    • 4
  • Jianzeng Dong
    • 1
  • Changsheng Ma
    • 1
    Email author
  1. 1.Beijing Anzhen HospitalCapital Medical UniversityBeijingChina
  2. 2.Strategic Medical AffairsJohnson & Johnson Medical (China) Ltd.ShanghaiChina
  3. 3.Shanghai Centennial Scientific Ltd., Inc.ShanghaiChina
  4. 4.Health Economic Research InstituteSun-Yat-sen UniversityZhongshanChina

Personalised recommendations